BonesLabsBlog
Back to all posts
Uncategorized

MGF

MGF (Mechano-Growth Factor, IGF-1Ec): The Mechanically Induced IGF-1 Splice Variant

Research summary. Mechano-Growth Factor (MGF), also known as IGF-1Ec, is a splice variant of insulin-like growth factor 1 (IGF-1) that is upregulated in skeletal muscle in response to mechanical loading and damage. It is generated through alternative splicing of the IGF1 gene, distinguished from the dominant IGF-1Ea isoform by a unique C-terminal E-domain peptide. Research-supplier MGF preparations typically refer either to the full IGF-1Ec splice variant or, more commonly, to a synthetic peptide corresponding to the unique C-terminal E-domain ("MGF C-terminal peptide" or "MGF Ec"), which is the focus of much of the experimental literature.

Molecular profile

  • Origin: Alternative splice product of the IGF1 gene, expressed in mechanically loaded skeletal muscle
  • Distinguishing feature: A unique 24-amino-acid C-terminal E-domain (Ec peptide) generated by retention of exon 5 with an inserted base shift
  • Class: Growth-factor splice-variant peptide / IGF-1 family member
  • Note on nomenclature: "MGF" in research-supplier contexts most commonly refers to the synthetic Ec C-terminal peptide rather than the full mature growth-factor protein. PEGylated forms (PEG-MGF) are addressed in a separate post.

Mechanism of action

The mature IGF-1 protein and the MGF C-terminal Ec peptide are now generally interpreted as having distinct biological activities:

  • Mature IGF-1 component. Once cleaved from the prepropeptide, the mature IGF-1 portion of an IGF-1Ec transcript signals through the IGF-1 receptor (IGF-1R), driving the canonical PI3K/Akt and MAPK pathways that mediate satellite-cell proliferation, protein synthesis, and survival signalling.
  • MGF E-domain peptide. The unique 24-residue C-terminal peptide (the "Ec" peptide) appears to act through a distinct, non-IGF-1R-mediated mechanism. Research has reported that synthetic Ec peptide drives myoblast proliferation while delaying myoblast differentiation, in contrast to mature IGF-1 which promotes both proliferation and differentiation. The receptor target for the E-domain peptide remains incompletely characterised; G-protein-coupled and non-classical signalling pathways have been proposed.

This functional split is biologically important: the mature IGF-1 component is interpreted as the long-term anabolic/survival signal, while the Ec peptide is interpreted as an early, transient proliferative signal that expands the satellite-cell pool before differentiation cues arrive.

Preclinical research highlights

Skeletal muscle mechanical loading and repair. A foundational body of research from the Goldspink laboratory at University College London established that MGF/IGF-1Ec expression rises sharply in skeletal muscle following mechanical loading or injury, in a pattern distinct from that of the IGF-1Ea isoform. Subsequent rodent and cell-culture work has reported that exogenous Ec peptide expands the satellite-cell pool and supports muscle-fibre repair in injury models.

Cardiac muscle. Cardiac research has reported that MGF expression is upregulated in response to ischaemia and mechanical stress, and that exogenous MGF or MGF Ec peptide is associated with reductions in cardiomyocyte apoptosis and improved post-infarct functional parameters in rodent models.

Bone repair. Rodent and lagomorph studies have reported that MGF administration accelerates osteoblast proliferation and bone-defect healing relative to vehicle controls.

Aging biology. Research has reported that the IGF-1Ec splicing response to mechanical loading is blunted in aged skeletal muscle, contributing to the broader age-related decline in muscle adaptation to exercise. This has motivated continued interest in the MGF system in sarcopenia research.

Limitations and interpretation

Several caveats are important when reading MGF literature:

  • The biological distinction between mature IGF-1 and the Ec peptide is not always clearly preserved in commercial product descriptions, and "MGF" can refer to either entity depending on context.
  • The receptor for the Ec peptide remains incompletely characterised, which complicates mechanistic interpretation of dose-response relationships.
  • The unmodified Ec peptide has a very short plasma half-life, motivating development of PEGylated analogues (PEG-MGF) for studies requiring sustained exposure.
  • Much of the human-relevant literature is at the level of muscle-biopsy gene-expression analysis rather than exogenous peptide administration in controlled trials.

Current research status

MGF / IGF-1Ec and its synthetic Ec C-terminal peptide are investigational research compounds. They are not FDA-approved for any indication. Research interest is concentrated in skeletal-muscle, cardiac, and bone-repair models, and in the basic biology of mechanical-load-responsive splicing. No registered late-stage clinical-trial programmes for exogenous MGF peptide therapeutics appear in major Western trial registries at the time of writing.

For research-supplier contexts, MGF and MGF C-terminal peptide are supplied as research-grade investigational peptides and are not intended for self-administration.

Key takeaways for researchers

  • MGF (IGF-1Ec) is an alternative-splicing variant of IGF-1, generated in mechanically loaded skeletal muscle by retention of an alternative E-domain.
  • "MGF" in research-supplier contexts most commonly refers to the synthetic 24-residue C-terminal Ec peptide rather than the full splice-variant protein.
  • The Ec peptide is interpreted as driving early myoblast proliferation while delaying differentiation, distinct from mature IGF-1 which promotes both.
  • Reported preclinical effects span skeletal-muscle repair, cardiac protection, bone repair, and engagement with aging biology.
  • MGF is not FDA-approved; PEGylated MGF (PEG-MGF) is a half-life-extended analogue covered separately.

References

  1. Yang S, Alnaqeeb M, Simpson H, Goldspink G. Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch. J Muscle Res Cell Motil. 1996;17(4):487–495.
  2. Hill M, Goldspink G. Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage. J Physiol. 2003;549(Pt 2):409–418.

This article is provided for educational and research purposes only. MGF (IGF-1Ec) and MGF C-terminal peptide are research compounds. They are not approved drugs or therapeutic agents and are not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving these compounds should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.

MGF | BonesLabs